Executive Medical Director, RLT

Responsibilities:                                                                                                                

• Lead the global medical affairs strategy for Radioligand Therapies (RLT) across early development, launch and in‑market phases, ensuring alignment across the full portfolio lifecycle.
• Shape integrated evidence and lifecycle strategies using innovative methodologies, including interventional, non‑interventional and real‑world evidence studies, to inform portfolio prioritisation and investment decisions.
• Provide strategic medical leadership to guide lifecycle planning and influence portfolio and governance decisions across global functions and senior cross‑functional forums.
• Partner closely with Development, Regulatory, Commercial and regional Medical Affairs teams to ensure patient, clinical, regulatory and access needs shape study design and execution.
• Drive the creation and delivery of robust global medical launch plans, including field medical readiness, education and scientific communication strategies across priority markets.
• Represent the global medical perspective with credibility in senior stakeholder interactions, cross‑functional governance forums and high‑impact external engagements.
• Champion the voice of patients by embedding unmet needs, real‑world insights and patient perspectives into global evidence generation and medical strategies.
• Ensure all medical activities meet the highest standards of quality, ethics, compliance and scientific integrity across a complex, matrixed global organisation.
• Build, strengthen and lead global medical expert networks, including key opinion leaders, investigators and academic partners, to elevate scientific exchange and external engagement.
• Track, optimise and report on medical plan performance, ensuring timely, cost‑effective execution and efficient use of resources across global programmes.

Essential for the role:

• Advanced degree in a health‑related field (Doctor of Medicine strongly preferred; Doctor of Philosophy or Doctor of Pharmacy also considered).
• Significant pharmaceutical industry experience within global medical affairs and/or clinical development, gained in a complex, matrixed organisation, with demonstrated impact at global level.
• Proven experience in oncology and/or Radioligand Therapies, including contribution to early asset strategy, pre‑launch planning, global launch execution, and lifecycle management.
• Strong strategic mindset with a proven track record of influencing senior stakeholders and enabling cross‑functional decision‑making across global governance forums.
• Demonstrated experience shaping and delivering global medical strategy across multiple development phases, from early clinical assets through launch and post‑launch optimisation.
• Extensive experience delivering complex global evidence generation programmes to a high scientific and ethical standard, on time and within scope.
• Deep understanding of clinical research principles, regulatory frameworks, healthcare systems, and ethical standards, with a strong background in clinical research and collaboration with academic institutions and external partners.
• Established credibility as a peer expert with external medical leaders, investigators, and scientific communities, and a proven ability to collaborate effectively across global functions, regions, and therapeutic areas.

Commitment to Diversity & Inclusion:

Novartis is committed to building an outstanding, inclusive work environment and diverse teams representative of the patients and communities we serve.

Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each other. Combining to achieve breakthroughs that change patients’ lives. Ready to create a brighter future together? https://www.novartis.com/about/strategy/people-and-culture

Benefits and Rewards: Learn about all the ways we’ll help you thrive personally and professionally.
Read our handbook (PDF 30 MB)